Paxlovid

Treatment of COVID-19

Paxlovid is used to treat mild-to-moderate COVID-19 in people who have received a positive viral test. It is specifically intended for individuals who have risk factors that make them more likely to develop severe illness, which may result in hospitalization or death.

This medication is authorized for use in the following groups:

• Adults.
• Children 12 years of age and older who weigh at least 40 kilograms (about 88 pounds).

For the treatment to be effective, it must be started as soon as possible after a diagnosis is made and within five days of when symptoms first began.

Limitations of Use

Paxlovid is not used for the following situations:

• To prevent COVID-19 before or after you have been exposed to the virus.
• To treat patients who are already hospitalized due to severe or critical COVID-19.

How Paxlovid Fights COVID-19

Paxlovid is a combination of two different antiviral medications: nirmatrelvir and ritonavir. Each drug plays a specific role in stopping the SARS-CoV-2 virus from spreading through the body.

Stopping Viral Replication

Nirmatrelvir is the primary active ingredient that fights the virus. It works by blocking an enzyme called a protease. The virus needs this specific enzyme to cut long chains of proteins into smaller pieces, which are then used to build new virus particles. When this enzyme is blocked, the virus cannot make copies of itself, which helps lower the amount of virus in the body.

Boosting the Medication

Ritonavir does not treat COVID-19 directly. Instead, its job is to help the nirmatrelvir work better. It slows down the process by which the liver breaks down nirmatrelvir. By doing this, ritonavir ensures that nirmatrelvir stays in the bloodstream at a high enough level for a longer duration to effectively combat the infection.

By interfering with the life cycle of the virus, Paxlovid helps the immune system gain the upper hand, which can prevent the infection from progressing to a more severe stage.

Common Side Effects

The most frequently reported side effects of Paxlovid include:

• Altered sense of taste: Many people report a metallic or bitter taste in the mouth (dysgeusia) during treatment.
• Diarrhea: Loose or frequent bowel movements may occur.
• Increased blood pressure: Some patients experience a temporary rise in blood pressure.
• Muscle aches: General body or muscle pain (myalgia) has been reported.
• Nausea: Feeling sick to the stomach or experiencing abdominal pain.

Serious Side Effects

While less common, some side effects require immediate medical attention. Seek help right away if you experience:

• Allergic reactions: Symptoms may include skin rash, hives, itching, swelling of the face, lips, or tongue, and difficulty breathing or swallowing.
• Liver problems: Signs of liver injury include yellowing of the skin or the whites of the eyes (jaundice), dark-colored urine, pale stools, pain in the upper right stomach area, or loss of appetite.

Some individuals may experience a return of COVID-19 symptoms or a new positive test result shortly after completing the five-day course of Paxlovid. This is often referred to as COVID-19 rebound.

Drug Interactions

Paxlovid contains ritonavir, which is a strong inhibitor of the CYP3A enzyme. This can lead to significantly increased levels of other medications, potentially causing serious or life-threatening reactions. Conversely, certain drugs that induce this enzyme can lower Paxlovid levels, making it less effective. A comprehensive review of all medications, including supplements and herbal products like St. John’s Wort, is required before use.

Hypersensitivity Reactions

Serious allergic reactions, such as anaphylaxis and severe skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis), have been reported. If symptoms of an allergic reaction occur—such as skin rash, hives, swelling of the face, or difficulty swallowing—the medication should be stopped immediately.

Hepatotoxicity

Elevations in liver enzymes, hepatitis, and jaundice have been observed in some patients. Caution is warranted in individuals with pre-existing liver disease or enzyme abnormalities. Paxlovid is not recommended for those with severe liver impairment.

Renal Impairment

Dose adjustments are necessary for patients with moderate kidney disease. The medication is not recommended for patients with severe kidney impairment.

HIV-1 Resistance

In individuals with undiagnosed or untreated HIV-1 infection, the use of Paxlovid may lead to the development of HIV-1 resistance to protease inhibitor drugs. This could complicate future HIV treatment regimens.

Pregnancy

There are currently no human studies available to determine the safety of Paxlovid use during pregnancy. Healthcare providers evaluate the use of this medication by weighing the potential benefits against the risks of severe COVID-19, which is known to increase the risk of complications for both the pregnant person and the fetus.

The two components of Paxlovid have different levels of available data:

• Nirmatrelvir: Animal studies did not show evidence of harm to fetal development at doses much higher than those used in humans.
• Ritonavir: This medication has been used for many years to treat HIV during pregnancy, and its safety profile in pregnant individuals is well-documented.

Breastfeeding

It is not known if nirmatrelvir passes into human breast milk. Ritonavir is known to be present in human milk, but the effects on the nursing infant or on milk production are currently unknown. Individuals who are breastfeeding should consult with their doctor to determine the best course of action during treatment.

Contraception

Paxlovid can interact with hormonal contraceptives, such as birth control pills, patches, or rings, potentially making them less effective. Patients using hormonal birth control are advised to use an effective alternative or a barrier method (such as condoms) while taking Paxlovid and for one menstrual cycle after the final dose.

Available Forms

Paxlovid is available as tablets for oral use. The medication is provided in blister cards that contain separate tablets for the different components of the treatment.

The treatment consists of:

• Nirmatrelvir tablets
• Ritonavir tablets

These tablets are co-packaged together in daily blister cards. Different versions of these cards are available to accommodate specific medical needs, such as for patients with kidney issues, but the form is always tablets.

FDA Approval and Authorization

Paxlovid (nirmatrelvir and ritonavir) received full FDA approval in May 2023 for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe disease, including hospitalization or death. This approval followed its initial release under Emergency Use Authorization (EUA) in December 2021.

Pediatric Use

While approved for adults, Paxlovid remains available under an EUA for pediatric patients aged 12 to 17 years who weigh at least 40 kilograms (about 88 pounds). These patients must also be at high risk for progression to severe COVID-19.

Regulatory Requirements and Safety

The FDA requires that Paxlovid be started as soon as possible after a COVID-19 diagnosis and within five days of symptom onset. Regulatory labeling emphasizes significant drug-drug interactions, as ritonavir can affect the metabolism of many other medications. Healthcare providers are instructed to review all concurrent medications before prescribing.

Limitations of Use

Paxlovid is not authorized or approved for the following uses:

• Pre-exposure or post-exposure prevention (prophylaxis) of COVID-19.
• Treatment of patients requiring hospitalization due to severe or critical COVID-19.
• Use for longer than five consecutive days.

The FDA has not issued a boxed warning for Paxlovid, but the prescribing information contains significant warnings regarding potential drug interactions and the risk of hypersensitivity reactions.

Purpose and Use

Paxlovid is prescribed to treat mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg). It is specifically for those who have tested positive for the virus and are at high risk for progressing to severe disease, which may lead to hospitalization or death.

How It Works

The treatment consists of two different medications packaged together:

• Nirmatrelvir: This drug blocks a specific enzyme that the SARS-CoV-2 virus needs to replicate itself in the body.
• Ritonavir: This component does not treat the virus directly but helps maintain higher levels of nirmatrelvir in the body for a longer period by slowing its breakdown.

Timing and Administration

For the medication to be effective, it must be started as soon as possible after a COVID-19 diagnosis and within five days of the first symptoms appearing. It is taken orally twice a day for five consecutive days.

Limitations

Paxlovid is not used for the following purposes:

• Preventing COVID-19 before or after exposure to the virus.
• Treating patients who already require hospitalization due to severe or critical COVID-19.
• Use for longer than five consecutive days.